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Abstract
Objective—We examined associations of IRS1 genetic variation with adiposity and metabolic 
profile in US Hispanic/Latino individuals of diverse backgrounds.
Methods—Previously genome-wide association study identified IRS1 variants (rs2943650, 
rs2972146, rs2943641, and rs2943634) as related to body fat percentage (BF%) and multiple 
metabolic traits were tested among up to 12,730 adults (5232 men; 7515 women) from the 
Hispanic Community Health Study/Study of Latinos.
Results—The C-allele (frequency=26%) of rs2943650 was significantly associated with higher 
BF% in overall (β=0.34±0.11% per allele; P=0.002) and in women (β=0.41±0.14% per C-allele; 
P=0.003), but not in men (β=0.28±0.18% per C-allele; P=0.11), though there was no significant 
sex-difference. Using the inverse-normal-transformed data to compare effect sizes, we found that 
the association with BF% was stronger in Hispanic/Latino women than that previously reported in 
European women (β=0.054±0.018SD vs β=0.008±0.011SD per C-allele; P=0.03). We also 
observed that the BF%-increasing allele of rs2943650 was significantly associated with lower 
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levels of fasting insulin, HOMA-IR, Hemoglobin A1c and triglycerides, and higher HDL-
cholesterol (P<0.05).
Conclusions—Our study confirmed and extended previous findings of IRS1 variation associated 
with increased adiposity but a favorable metabolic profile in US Hispanics/Latinos, with a 
relatively stronger genetic effect on BF% in Hispanic/Latino women compared to European 
women.
Keywords
Adiposity; Cardiovascular Risk; Insulin resistance; Genetics; Hispanics
Introduction
Obesity is associated with insulin resistance, dyslipidemia and hypertension, and therefore 
represents a major risk factor for a number of metabolic diseases (1). However, most 
interestingly, a large-scale meta-analysis of genome-wide association studies (GWAS) for 
body fat percentage (BF%) identified a variant of which the adiposity-increasing allele is 
associated with favorable metabolic outcomes (2), illustrating the complexity of the 
relationship between obesity and metabolic diseases. Specifically, the C-allele 
(frequency=36%) of a common single nucleotide polymorphism (SNP), rs2943650, near 
IRS1 (insulin receptor substrate 1), was found to be associated with higher BF%, but also 
with a favorable metabolic profile (2). Other SNPs near IRS1, all in high linkage 
disequilibrium (LD) with rs2943650 according to the HapMap CEU, have also been 
identified by GWAS for various metabolic traits, including insulin resistance and type 2 
diabetes (rs2943641; r2CEU = 1.0 with rs2943650) (3), triglycerides and HDL-cholesterol 
(rs2972146; r2CEU = 0.95 with rs2943650)(4), and coronary artery disease (rs2943634, 
r2CEU = 0.83 with rs2943650) (5). These GWAS findings are in line with the biological 
function of IRS1, which plays a key role in the insulin signaling pathway (6, 7), but an 
understanding of observed associations of IRS1 variants with both increased adiposity and a 
favorable metabolic profile remains incomplete. In addition, most previous studies are 
restricted to populations of European ancestry (2, 3, 4, 5), and only limited information 
regarding these intriguing findings on IRS1 variants is available in other ethnic groups. 
Associations of the IRS1 variants with insulin resistance and hyperglycemia have been 
confirmed in a cohort of Puerto Ricans living in Boston (8). However, this study did not 
report on association with BF%, and the participants did not represent the full diversity of 
US Hispanics/Latinos.
US Hispanics/Latinos are disproportionately affected by obesity and related metabolic 
diseases (9, 10). Elevated levels of adiposity traits, including higher BF%, are associated 
with increased prevalence of diabetes, dyslipidemia and hypertension, as well as unfavorable 
levels of metabolic biomarkers, in the Hispanic Community Health Study/Study of Latinos 
(HCHS/SOL) (11), a population-based cohort of US Hispanics/Latinos. In the current study, 
we examined whether the previously observed association of SNPs near IRS1 with adiposity 
and metabolic traits are also observed in up to 12,747 individuals of diverse Hispanic/Latino 
backgrounds from the HCHS/SOL.
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The HCHS/SOL is a population-based study of 16,415 Hispanic/Latino adults living in four 
U.S. metropolitan areas (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA). To be 
eligible, individuals had to be 18–74 years old at recruitment; self-identify as Hispanic/
Latino; able to travel to the local study field center; and no plans to move out of the study 
area. Participants were recruited using a two-stage probability sample design, as described 
previously (12). Of 39,384 individuals who met eligibility criteria, 41.7% enrolled, 
representing 16,415 persons from 9,872 households. A comprehensive battery of interviews 
relating to personal and family characteristics, health status and behaviors, and a clinical 
assessment with blood draw, were conducted at an in-person clinic baseline visit during 
2008–2011. In the current study, a total of up to 12,747 participants who consented to 
participate genetic studies were included. The study was approved by the Institutional 
Review Boards at all participating institutions, and all participants gave written informed 
consent.
Measurements
Measurements of weight and BF% were obtained from the Tanita body composition 
analyzer (model TBF-300A; Tanita Corporation, Arlington Heights, IL). Height and waist 
and hip circumference were measured to the nearest centimeter based on a standard protocol 
(www.cscc.unc.edu/hchs). Body weight was measured to the nearest 0.1 kg. Body mass 
index (BMI) was calculated as weight in kilograms divided by height in meters squared. 
Blood samples (fasting and after a 2-hour oral glucose load) were collected and processed 
according to standardized protocols (www.cscc.unc.edu/hchs). Total serum cholesterol was 
measured using a cholesterol oxidase enzymatic method and HDL cholesterol with a direct 
magnesium/dextran sulfate method. LDL cholesterol was calculated using the Friedewald 
equation (13). Plasma glucose was measured using a hexokinase enzymatic method (Roche 
Diagnostics). Hemoglobin A1c (HbA1c) was measured using a Tosoh G7 Automated HPLC 
Analyzer (Tosoh Bioscience). Fasting insulin was measured using two commercial 
immunoassays (ELISA, Mercodia AB, Uppsala, Sweden; and sandwich immunoassay on a 
Roche Elecsys 2010 Analyzer, Roche Diagnostics, Indianapolis, IN); early measures 
conducted with the Mercodia assay were calibrated, and values were equivalent to the Roche 
method. Homeostatic model assessment of insulin resistance (HOMA-IR) was computed 
based on the following equation: fasting glucose × fasting insulin/405 (14).
Genotype data
Four SNPs (rs2943650, rs2972146, rs2943641, and rs2943634) near IRS1, previously 
identified in GWAS for BF%, insulin resistance and type 2 diabetes, blood lipids, and 
coronary artery disease (2, 3, 4, 5), were analyzed in the current study. Genotype data on 
SNPs rs2943641 and rs2943634 were derived from the HCHS/SOL Custom array 
(15041502 B3), which consists of the Illumina Omni 2.5M array (HumanOmni2.5-8v1-1) 
plus ~150k custom SNPs. Genotype and quality control (QC) were performed by Illumina 
Microarray Service at LA Biomed and the HCHS/SOL Genetic Analysis Center. The QC 
process and quality filters used at HCHS/SOL Genetic Analysis Center have been previously 
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described (15, 16). SNPs rs2943650 and rs2972146 were imputed based on the 1000 
Genomes Project phase 1 reference panel including Hispanic/Latino populations (i.e., 
Mexicans, Colombians and Puerto Ricans), using SHAPEIT2 (v2.r644) (17) and IMPUTE2 
(v2.3.0) (18), both with almost perfect imputation scores (info= 0.998 and 0.999, 
respectively). Genetic principal components (PC) and kinship coefficients (KC) were 
calculated using PC-AiR and PC-Relate to provide PC estimates robust to relatedness and 
KC estimates robust to population structure, admixture and deviations from Hardy-Weinberg 
Equilibrium (16).
Identification of Hispanic/Latino background
Individuals were classified into six “genetic analysis subgroups” (Hispanic/Latino 
background groups: Cuban, Dominican, Puerto Rican, Mexican, Central American, or South 
American) based on their self-reported background and position in the n-dimensional space 
defined by the first 5 genetic principal components (PCs) (16). For each group, a 99% 
tolerance hyper-ellipsoid was defined based on individuals who also self-reported as that 
background. Individuals within the hyper-ellipsoid for their self-reported background group 
were assigned to the corresponding genetic analysis group. Individuals who were outside the 
hyper-ellipsoid for their self-reported background group (or those who self-reported as 
“Other” or “Mixed") were assigned to the genetic analysis group with the closest hyper-
ellipsoid center. The concordance between the six genetic analysis subgroups and the 
specific Hispanic/Latino background groups reported by participants is very high (range 92–
98%, mean 96%).
Statistical analysis
We used a linear mixed model (LMM) to examine associations of IRS1 variants with BF% 
and other metabolic traits, adjusted for fixed effect covariates, including age, sex, field 
center, sampling weights, Hispanic/Latino background (six genetic analysis subgroups), and 
the first five PCs. Genetic relatedness (a matrix of pairwise kinship coefficients), household 
membership and census block group membership were also modeled as random effects to 
account for correlation between trait values of individuals. Variance components for each 
random effect were estimated under the null model (no genotype main effect) using Average 
Information Restricted Maximum. For each SNP, the effect size (Beta) and its standard error 
(SE) were estimated by using generalized least squares with the trait covariance structure 
estimated from the null model. A Wald test was performed to test for association at each 
SNP. Because associations between IRS1 variants and BF% were previously reported to be 
more pronounced in men than in women (2), all analyses were also performed in men and 
women separately. In addition, associations with BF% were also stratified by Hispanic/
Latino background (6 genetic analysis subgroups).
For individuals using lipid-lowering medications, we added a constant to each of their lipid 
traits, of which the amount was determined by the class of medication used (19). 
Associations with glycemic traits (fasting glucose, fasting insulin, HbA1c, 2-hour glucose, 
and HOMA-IR) were tested in individuals without diabetes. As distributions for BMI, 
triglycerides, fasting insulin and HOMA-IR were right-skewed, values were natural log-
transformed before the analyses. Waist circumference and Waist-to-hip ratio (WHR) were 
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also adjusted for BMI. All association analyses were repeated after inverse normal 
transformation of residuals after fitting the null model to an approximate mean of 0 and an 
approximate SD of 1, allowing comparison of effect sizes across different traits.
Results
Description of genotype and phenotype data
Among the 12,747 US Hispanics/Latinos (5,232 men and 7,515 women) included in the 
analyses, Hispanic/Latino backgrounds were: 11% Central American, 18% Cuban, 9% 
Dominican, 37% Mexican, 18% Puerto Rican, and 7% South American. In addition, 20% of 
participants had diabetes, and 5% of participates had self-reported coronary heart disease. 
The mean (SD) of BF% is 28.1 (8.2)% in men and 38.9 (7.7)% in women (Table 1).
The previously identified BF%-associated variant, rs2943650, showed moderate-to-strong 
LD with the other three IRS1 variants, rs2943634 (r2=0.65), rs2943641 (r2=0.75), and 
rs2972146 (r2=0.64), in US Hispanics/Latinos (Supplemental Table 1), while these variants 
showed a high LD pattern in Europeans (r2>0.8, according to HapMap CEU). The minor 
allele frequency (MAF) of the variant rs2943650 (C-allele) was 29%, and varied across 
Hispanic/Latino backgrounds, ranging from 20% in Mexicans to 49% in Dominicans 
(Supplemental Table 2).
IRS1 variants, body fat percentage and other adiposity traits
In a pooled analysis of all participants, the minor allele (C-allele) of rs2943650 was 
significantly associated with higher BF% (β=0.34 ± 0.11% per allele; P=0.002) (Table 2). 
The association tended to be more pronounced in women (β=0.41± 0.18%; P=0.003) than in 
men (β=0.28 ± 0.14%; P=0.11), but this sex difference was not significant. Using the 
inverse-normal-transformed data to compare effect sizes, we found that the association with 
BF% was stronger in Hispanic/Latino women than that previously reported in European 
women (β=0.054 ± 0.018SD vs β=0.008 ± 0.011SD; P=0.03), while there was no significant 
difference between Hispanic/Latino men and European men (β=0.032 ± 0.022SD vs 
β=0.035 ± 0.009SD; P=0.88) (data in Europeans were reported by Kilpeläinen et al. (2)). In 
addition, the minor allele (C-allele) of rs2943650 was significantly associated with higher 
BMI (natural log-transformed) (β=0.007±0.003; P=0.013), but not associated with BMI-
adjusted waist circumference (P=0.77) or WHR (P=0.92) (Supplemental Table 3).
Consistent with the modest LD between the four IRS1 SNPs, the associations of the other 
three IRS1 variants with BF% was consistent with those observed for rs2943650 (Table 2). 
We examined whether either of the four variants was driving the observed associations using 
conditional analyses, but found no evidence for any one being the lead SNP, suggesting that 
they all represent the same signal within or near the IRS1 locus.
We further examined associations between rs2943650 and BF% among individuals with 
different Hispanic/Latino backgrounds separately. The minor-allele of rs2943650 showed 
significant associations (Cuban and Dominican) or non-significant associations (Central 
American, Mexican and Puerto Rican) with higher BF% among five of the six Hispanic/
Latino background groups, whereas a non-significant trend toward an inverse association 
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was observed in South Americans (Figure 1). However, there was no statistically significant 
heterogeneity between groups (P>0.27; Cochran’s Q test). Moreover, we examined 
associations between rs2943650 and BF% in men and women separately within each 
Hispanic/Latino background group, and did not find significant sex difference (All P>0.05) 
(Supplemental Table 4). However, a nominal-significant inverse association between 
rs2943650 and BF% was observed in men of South American group (P=0.027).
IRS1 variants and metabolic traits
We then examined the associations of the IRS1 variants with multiple metabolic traits 
(Supplemental Table 3; Figure 2). The minor allele (BF%-increasing-allele) of rs2943650 
was significantly associated with lower HbA1c (P=0.003), higher HDL cholesterol 
(P=0.002), and lower triglycerides (P=0.03); and these associations remained significant 
after further adjusting for BF%. Using the inverse-normal-transformed data, the effect size 
of rs2943650 minor allele on BF% (0.041 ± 0.014 SD per allele) was similar with that on 
HbA1c (−0.043 ± 0.014 SD per allele), and slightly larger than those on HDL cholesterol 
(0.033 ± 0.014 SD per allele) and triglycerides (−0.027 ± 0.014 SD per allele) (Figure 2). 
After adjustment for multiple tests for one genetic variant (4 SNPs are in the moderate-to-
strong LD) and 11 independently measured traits (we did not count HOMA-IR which was 
calculated based on fasting insulin and glucose), associations of rs2943650 with BF%, 
HbA1c and HDL-c remained significant (P<0.0045).
Generally similar results were observed for the other three IRS1 variants (Supplemental 
Table 3). The minor allele of IRS1 variants were associated with lower fasting insulin 
(P=0.08 to 0.01) and lower HOMA-IR (P=0.08 to 0.009) after, but not before, adjusting for 
BF% (Supplemental Table 3). In addition, associations of IRS1 variants with adiposity 
measures and lipids did not materiality change in sensitivity analysis after we excluded 
participants with diabetes and self-reported coronary heart disease (Supplemental Table 5).
Discussion
In the present study, we confirmed and extended previous findings (2, 8) that genetic 
variation near IRS1 associates with increased adiposity, but a favorable metabolic profile 
(low levels of fasting insulin, HOMA-IR, HbA1c and triglyceride, and high HDL cholesterol 
levels) among individuals of diverse Hispanic/Latino backgrounds. In addition, we also 
found a relatively stronger genetic effect on BF% in Hispanic/Latino women than that 
previously reported in European women.
Previous data in Europeans showed that the association between IRS1 rs2943650 variant and 
BF% was more pronounced in men than in women (2), while we did not observe such sex-
difference in US Hispanics/Latinos. Moreover, our further analysis indicated that the genetic 
effect on BF% was larger in Hispanic/Latino women than that in European women, but there 
was no significant difference between Hispanic/Latino men and European men. It has been 
speculated that the previously observed relatively weaker genetic effect on adiposity in 
women might be related to more subcutaneous fat in women driven by hormones compared 
to men (20), which may attenuate the influence of IRS1 variation on subcutaneous fat (2). 
However, it is unclear whether the observed ethnic-difference in genetic effect is related to 
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different fat deposition between Hispanic/Latino women and European women. Hispanic/
Latino women have higher prevalence of obesity (9) and higher BF% than non-Hispanic 
white women (21, 22), but comparison of accurate fat deposition between them need further 
investigations. In addition, it is should be noted that the previous GWAS in Europeans 
included multiple cohorts using bioimpedance analysis (BIA) and/or dual-energy X-ray 
absorptiometry (DEXA) measures (2), while we used Tanita-BIA to estimate BF%. 
However, our method has been reported to have good agreement with DEXA in Hispanics/
Latinos (23), and similar results between using BIA and DEXA measures were reported in 
the previous GWAS in Europeans (2)..
Genetic heterogeneity in associations with adiposity measures (e.g., BF% and WHR) 
between men and women (sex-specific effect) has been observed in previous studies. For 
example, a number of loci (including IRS1) have shown significant sex-specific effects on 
BMI-adjusted WHR and BF% in recent GWAS (2, 24, 25). In addition, a few SNPs 
exhibited significant evidence for heterogeneity of effect on BMI between ethnic groups, but 
it remains unclear whether these results may reflect true heterogeneity or are due to (LD) 
differences across ancestries (25). Nevertheless, recent large GWAS meta-analyses including 
multiple ethnic groups considering genetic heterogeneity provides insight into the genetic 
architecture of complex metabolic diseases (25, 26). However, ethnic-specific effects of BF
%-associated SNPs have not been well-examined as previous studies included most 
individuals of European-ancestry but few of non-European-ancestry (2, 24). Thus, the 
observed ethnic-difference in women needs validation, and future studies using same 
methods with more accurate adiposity measures across different ethnic groups might help 
clarify this interesting finding.
One unique element of this study is the diversity of Hispanic/Latino backgrounds in our 
sample. Previous genetic studies on obesity and related metabolic outcomes conducted in 
US Hispanics/Latinos have largely examined individuals of single background (mostly 
Mexicans) or unidentified origins (8, 27, 28, 29, 30). However, the complexity of the 
biological and cultural diversity within US Hispanics/Latinos has been well-acknowledged. 
Our genetic analysis identified six genetic groups (Cuban, Dominican, Puerto Rican, 
Mexican, Central American, or South American), which are highly consistent with the self-
reported Hispanic/Latino backgrounds. In our study, associations with higher BF% were 
generally consistent among these groups, except for the South American group which 
showed a non-significant inverse association between the rs2943650 and BF%. This 
discrepancy might be also due to relatively small sample size, different phenotype and/or 
genotype distributions, since South American group was the smallest group, and had the 
lowest BF% and MAF of SNPs among 6 Hispanic background groups. Nevertheless, there 
was no significant heterogeneity across groups.
In addition to the confirmed associations of IRS1 variants with fasting insulin, HOMA-IR, 
HDL cholesterol and triglycerides (2, 3, 4), a novel finding of our study is the significant 
association between IRS1 variants and HbA1c levels. Given the well-established role of 
IRS1 in insulin resistance, it is possible that the observed associations with HbA1c might be 
through the regulation of blood glucose. A recent study suggested that the IRS1 G972R 
missense is associated with uncontrolled diabetes (e.g., HbA1c >8%) through interaction 
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with oral anti-diabetes drugs among patients with type 2 diabetes (31). However, IRS1 
variants were not associated with HbA1c levels in previous GWAS among Europeans and 
Asians (32, 33). Moreover, IRS1 variants were associated with insulin resistance to a lesser 
extent (only significant after adjusting for BF%) and were not associated with fasting 
glucose in our study of US Hispanics/Latinos, suggesting other pathways beyond glucose 
metabolism might be involved (32, 33).
The mechanisms underlying the observed associations of IRS1 variants with both increased 
adiposity and a favorable metabolic profile remain unclear. Kilpeläinen et al. (2) found that 
the BF%-increasing allele of rs2943650 was associated with increased abdominal 
subcutaneous fat but not visceral fat, which may contribute to a favorable metabolic profile. 
This association suggests a role of the IRS1 locus in the distribution and storage of body fat. 
A number of studies have suggested that increased leg fat (mainly subcutaneous fat) is 
associated with favorable levels of metabolic traits, especially with low insulin resistance, 
low triglycerides and high HDL-cholesterol (34, 35, 36, 37), but no data on associations 
between IRS1 variants and leg fat have been published. On the other hand, our findings may 
also reflect the fact that high insulin sensitivity may promote lipid storage in adipocytes and 
thus results in increased adiposity. In line with this speculation, genetic scores of insulin 
sensitivity increasing alleles (including the IRS1 variant) have been associated with 
increased adiposity (38, 39). Indeed, the SNP rs2943650 is significantly associated with 
gene expression of IRS1 in subcutaneous adipose tissue (P=3.5×10−7) (data from the GTEx, 
http://www.gtexportal.org), suggesting a role of the IRS1 variant in regulating insulin 
signaling pathway in adipose tissue. However, we could not exclude the independent 
pleiotropic effects of IRS1 variants on adiposity and metabolic traits. A number of obesity-
susceptibility loci were found to show pleiotropic associations with various metabolic traits, 
and half of the significant associations were directionally inconsistent with the phenotypic 
correlations (40).
Major strengths of this study include a population-representative sample of US Hispanics/
Latinos of diverse backgrounds, and multiple adiposity and metabolic biomarkers measured. 
However, our study lacked data on regional fat deposition measured by DEXA, computed 
tomography or magnetic resonance imaging, as these approaches require high cost and time 
investment for large epidemiological studies. Other limitations of the study include the 
nature of cross-sectional data and hence a lack of data on incident diabetes and 
cardiovascular disease events. Future studies using longitudinal data may help clarify 
whether IRS1 variation first influence adiposity and then affect metabolic diseases, or 
whether these associations are independent.
In summary, this study generally confirmed the previous GWAS findings of IRS1 variants 
associated with increased adiposity and a favorable metabolic profile in US Hispanics/
Latinos. We also found a relatively stronger genetic effect on BF% in Hispanic/Latino 
women compared to European women. These findings further imply the complexity of 
biological and molecular mechanisms that link obesity with metabolic diseases. Studies with 
more accurate adiposity measures (e.g., regional fat deposition) are needed to further 
investigate relationships between IRS1 genetic variants, adiposity, and metabolic traits in US 
Hispanics/Latinos.
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What is already known about this subject?
• Adiposity is related to impaired metabolic profiles and adverse 
cardiovascular health outcomes.
• IRS1 genetic variation has been associated with elevated body fat 
percentage but a favorable metabolic profile in non-Hispanic White 
population.
• U.S. Hispanics/Latinos, especially Hispanic/Latino women, have 
higher prevalence of obesity and higher body fat percentage, compared 
to their non-Hispanic White counterparts.
What does this study add?
• We show among a novel, population-based sample of up to 12,730 
Hispanics/Latinos that IRS1 variation is associated with increased 
adiposity but favorable levels of metabolic biomarkers.
• Genetic effect of IRS1 variation on BF% is stronger in Hispanic/Latino 
women than that previously reported in non-Hispanic White women, 
while there is no significant difference between Hispanic/Latino men 
and non-Hispanic White men.
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Association between the SNP rs2943650 near IRS1 and Body fat percentage across 
Hispanic/Latino background groups.
*Data are effect size (95% confidence interval) for each minor allele of rs2943650 on body 
fat percentage (%), adjusted for age, sex, sampling weights, relatedness and population 
structure (kinship coefficients and eigenvectors). Overall results were pooled by fixed effect 
meta-analysis.
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Associations of the minor (C) allele of rs2943650 near IRS1 with obesity traits, glycemic 
traits and blood lipids.
All traits were inverse normally transformed to approximate normality (mean= 0, SD=1) in 
men and women separately, adjusted for age, sex (if appropriate), sampling weights, 
Hispanic/Latino background, relatedness and population structure (kinship coefficients and 
eigenvectors). Data are effect size and standard errors (error bars).
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Table 1
Characteristics of participants
All Men Women P for sex-
difference
No. of participants 12747 5232 7515 -
Hispanic/Latino background* -
  Central American 1397 (11) 568 (11) 829 (11)
  Cuban 2257 (18) 1062 (20) 1195 (16)
  Dominican 1180 (9) 410 (8) 770 (10)
  Mexican 4750 (37) 1877 (36) 2873 (38)
  Puerto Rican 2242 (18) 945 (18) 1297 (17)
  South American 921 (7) 370 (7) 551 (7)
Age, years 46.1 (13.9) 45.3 (14.2) 46.7 (13.6) <0.001
Diabetes, n (%) 2501 (20) 997 (19) 1504 (20) 0.01
Self-reported coronary artery
disease, n (%)
700 (5) 379 (7) 321 (4) <0.001
Body fat percentage, % 34.5 (9.5) 28.1 (8.2) 38.9 (7.7) <0.001
BMI, kg/m2 29.8 (6.1) 29.1 (5.3) 30.3 (6.5) <0.001
Waist circumference, cm 98.3 (13.9) 99.1 (13.4) 97.8 (14.3) <0.001
Waist-to-hip ratio 0.92 (0.08) 0.95 (0.07) 0.90 (0.07) <0.001
Fasting glucose, mg/dl 93.8 (8.3) 95.9 (8.2) 92.3 (8.1) <0.001
Fasting insulin, mU/L 12. 1(8.4) 12.1 (9.0) 12. 1(8.4) 0.88
HOMA-IR 2.8 (2.2) 2.9 (2.3) 2.8 (2.1) 0.009







HbA1c, % 5.47 (0.37) 5.45 (0.37) 5.47 (0.36) 0.001















Data are mean (SD) or n (%).
*
Hispanic/Latino background was defined based on their self-reported background and position in the n-dimensional space defined by the first 5 
genetic principal components (PCs).
†
These variables were adjusted to account for average effects of lipid medication use.
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